Discovering New Prognostic Biomarkers For Breast Cancer
Publié le
New prognostic biomarkers for breast cancer: A range of biological markers were analyzed by polymerase chain reaction and immunohistochemistry in…
Publié le
New prognostic biomarkers for breast cancer: A range of biological markers were analyzed by polymerase chain reaction and immunohistochemistry in…
Publié le
In this meta-analysis, tumor responses and survival were analyzed combining the data from the different trials using patient individual data. The…
Publié le
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…
Publié le
Meta-Analysis performed with IDDI’s Methodology Skills IDDI has been involved in numerous meta-analyses to directly or indirectly support new drug applications….
Publié le
Surrogate endpoint for overall survival We managed to prove, using data from a randomized trial comparing Ceplene + IL-2 to…
Publié le
IDDI organized its second free live webinar on DEVELOPMENT AND VALIDATION OF CLINICALLY USEFUL GENE SIGNATURES. This webinar reviewed statistical issues…
Publié le
A multi-center phase II trial was conducted in just over 100 patients to compare metabolic changes in the prostate after…
Publié le
IDDI organized a webinar on DESIGN AND ANALYSIS OF PHASE II TRIALS IN ONCOLOGY. This webinar presented key concepts and…
Publié le
IDDI announces the appointment of Dr. Everardo Saad as Senior Medical Expert as of July 2014. Everardo brings over 12 years…